2023-06-012024-05-312024-05-31false09938370MMOR MEDICINES LTD2025-01-2047730falseiso4217:GBPxbrli:pure099383702023-06-01099383702024-05-31099383702023-06-012024-05-31099383702022-06-01099383702023-05-31099383702022-06-012023-05-3109938370bus:SmallEntities2023-06-012024-05-3109938370bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3109938370bus:FullAccounts2023-06-012024-05-3109938370bus:PrivateLimitedCompanyLtd2023-06-012024-05-3109938370core:WithinOneYear2024-05-3109938370core:AfterOneYear2024-05-3109938370core:WithinOneYear2023-05-3109938370core:AfterOneYear2023-05-3109938370core:ShareCapital2024-05-3109938370core:SharePremium2024-05-3109938370core:RevaluationReserve2024-05-3109938370core:OtherReservesSubtotal2024-05-3109938370core:RetainedEarningsAccumulatedLosses2024-05-3109938370core:ShareCapital2023-05-3109938370core:SharePremium2023-05-3109938370core:RevaluationReserve2023-05-3109938370core:OtherReservesSubtotal2023-05-3109938370core:RetainedEarningsAccumulatedLosses2023-05-3109938370core:LandBuildings2024-05-3109938370core:PlantMachinery2024-05-3109938370core:Vehicles2024-05-3109938370core:FurnitureFittings2024-05-3109938370core:OfficeEquipment2024-05-3109938370core:NetGoodwill2024-05-3109938370core:IntangibleAssetsOtherThanGoodwill2024-05-3109938370core:ListedExchangeTraded2024-05-3109938370core:UnlistedNon-exchangeTraded2024-05-3109938370core:LandBuildings2023-05-3109938370core:PlantMachinery2023-05-3109938370core:Vehicles2023-05-3109938370core:FurnitureFittings2023-05-3109938370core:OfficeEquipment2023-05-3109938370core:NetGoodwill2023-05-3109938370core:IntangibleAssetsOtherThanGoodwill2023-05-3109938370core:ListedExchangeTraded2023-05-3109938370core:UnlistedNon-exchangeTraded2023-05-3109938370core:LandBuildings2023-06-012024-05-3109938370core:PlantMachinery2023-06-012024-05-3109938370core:Vehicles2023-06-012024-05-3109938370core:FurnitureFittings2023-06-012024-05-3109938370core:OfficeEquipment2023-06-012024-05-3109938370core:NetGoodwill2023-06-012024-05-3109938370core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3109938370core:ListedExchangeTraded2023-06-012024-05-3109938370core:UnlistedNon-exchangeTraded2023-06-012024-05-3109938370core:MoreThanFiveYears2023-06-012024-05-3109938370core:Non-currentFinancialInstruments2024-05-3109938370core:Non-currentFinancialInstruments2023-05-3109938370dpl:CostSales2023-06-012024-05-3109938370dpl:DistributionCosts2023-06-012024-05-3109938370core:LandBuildings2023-06-012024-05-3109938370core:PlantMachinery2023-06-012024-05-3109938370core:Vehicles2023-06-012024-05-3109938370core:FurnitureFittings2023-06-012024-05-3109938370core:OfficeEquipment2023-06-012024-05-3109938370dpl:AdministrativeExpenses2023-06-012024-05-3109938370core:NetGoodwill2023-06-012024-05-3109938370core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3109938370dpl:GroupUndertakings2023-06-012024-05-3109938370dpl:ParticipatingInterests2023-06-012024-05-3109938370dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3109938370core:ListedExchangeTraded2023-06-012024-05-3109938370dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3109938370core:UnlistedNon-exchangeTraded2023-06-012024-05-3109938370dpl:CostSales2022-06-012023-05-3109938370dpl:DistributionCosts2022-06-012023-05-3109938370core:LandBuildings2022-06-012023-05-3109938370core:PlantMachinery2022-06-012023-05-3109938370core:Vehicles2022-06-012023-05-3109938370core:FurnitureFittings2022-06-012023-05-3109938370core:OfficeEquipment2022-06-012023-05-3109938370dpl:AdministrativeExpenses2022-06-012023-05-3109938370core:NetGoodwill2022-06-012023-05-3109938370core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3109938370dpl:GroupUndertakings2022-06-012023-05-3109938370dpl:ParticipatingInterests2022-06-012023-05-3109938370dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3109938370core:ListedExchangeTraded2022-06-012023-05-3109938370dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3109938370core:UnlistedNon-exchangeTraded2022-06-012023-05-3109938370core:NetGoodwill2024-05-3109938370core:IntangibleAssetsOtherThanGoodwill2024-05-3109938370core:LandBuildings2024-05-3109938370core:PlantMachinery2024-05-3109938370core:Vehicles2024-05-3109938370core:FurnitureFittings2024-05-3109938370core:OfficeEquipment2024-05-3109938370core:AfterOneYear2024-05-3109938370core:WithinOneYear2024-05-3109938370core:ListedExchangeTraded2024-05-3109938370core:UnlistedNon-exchangeTraded2024-05-3109938370core:ShareCapital2024-05-3109938370core:SharePremium2024-05-3109938370core:RevaluationReserve2024-05-3109938370core:OtherReservesSubtotal2024-05-3109938370core:RetainedEarningsAccumulatedLosses2024-05-3109938370core:NetGoodwill2023-05-3109938370core:IntangibleAssetsOtherThanGoodwill2023-05-3109938370core:LandBuildings2023-05-3109938370core:PlantMachinery2023-05-3109938370core:Vehicles2023-05-3109938370core:FurnitureFittings2023-05-3109938370core:OfficeEquipment2023-05-3109938370core:AfterOneYear2023-05-3109938370core:WithinOneYear2023-05-3109938370core:ListedExchangeTraded2023-05-3109938370core:UnlistedNon-exchangeTraded2023-05-3109938370core:ShareCapital2023-05-3109938370core:SharePremium2023-05-3109938370core:RevaluationReserve2023-05-3109938370core:OtherReservesSubtotal2023-05-3109938370core:RetainedEarningsAccumulatedLosses2023-05-3109938370core:NetGoodwill2022-06-0109938370core:IntangibleAssetsOtherThanGoodwill2022-06-0109938370core:LandBuildings2022-06-0109938370core:PlantMachinery2022-06-0109938370core:Vehicles2022-06-0109938370core:FurnitureFittings2022-06-0109938370core:OfficeEquipment2022-06-0109938370core:AfterOneYear2022-06-0109938370core:WithinOneYear2022-06-0109938370core:ListedExchangeTraded2022-06-0109938370core:UnlistedNon-exchangeTraded2022-06-0109938370core:ShareCapital2022-06-0109938370core:SharePremium2022-06-0109938370core:RevaluationReserve2022-06-0109938370core:OtherReservesSubtotal2022-06-0109938370core:RetainedEarningsAccumulatedLosses2022-06-0109938370core:AfterOneYear2023-06-012024-05-3109938370core:WithinOneYear2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3109938370core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3109938370core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3109938370core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3109938370core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3109938370core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3109938370bus:Director12023-06-012024-05-3109938370bus:Director22023-06-012024-05-3109938370bus:Director32023-06-012024-05-3109938370bus:Director42023-06-012024-05-3109938370bus:Director52023-06-012024-05-3109938370bus:Director62023-06-012024-05-3109938370bus:Director72023-06-012024-05-31

MMOR MEDICINES LTD

Registered Number
09938370
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

MMOR MEDICINES LTD
Company Information
for the year from 1 June 2023 to 31 May 2024

Directors

Dr D R T Knowles
Dr J Lomas
Dr E Ramsay
Dr R O Wace
Mr Z Z Musaji
Mr A K Sharma
Mrs G Sharma

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

09938370 (England and Wales)
MMOR MEDICINES LTD
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Investments3747,855747,855
747,855747,855
Current assets
Debtors4-274,637
Cash at bank and on hand6,5186,282
6,518280,919
Creditors amounts falling due within one year5(241,253)(474,543)
Net current assets (liabilities)(234,735)(193,624)
Total assets less current liabilities513,120554,231
Creditors amounts falling due after one year6(87,071)(155,241)
Accruals and deferred income(979)(979)
Net assets425,070398,011
Capital and reserves
Called up share capital1,0001,000
Profit and loss account424,070397,011
Shareholders' funds425,070398,011
The financial statements were approved and authorised for issue by the Board of Directors on 20 January 2025, and are signed on its behalf by:
Mr A K Sharma
Director
Registered Company No. 09938370
MMOR MEDICINES LTD
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Dividend income
Dividend income is recognised when the right to receive payment is established.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Investments
Investments in subsidiaries are measured at cost.
2.Average number of employees

20242023
Average number of employees during the year00
3.Fixed asset investments

Investments in groups1

Total

££
Cost or valuation
At 01 June 23747,855747,855
At 31 May 24747,855747,855
Net book value
At 31 May 24747,855747,855
At 31 May 23747,855747,855

Notes

1Investments in group undertakings and participating interests
4.Debtors: amounts due within one year

2024

2023

££
Amounts owed by group undertakings-274,637
Total-274,637
5.Creditors: amounts due within one year

2024

2023

££
Bank borrowings and overdrafts74,54374,543
Other creditors166,710400,000
Total241,253474,543
6.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts87,071155,241
Total87,071155,241
7.Related party transactions
Amounts owed by group undertakings is Nil (2023: £274,637) this relates to Lords Healthcare Ltd, which is a subsidiary of the company. Other creditors of £166,710 (2023: £400,000) relates to amounts owed to the shareholders.